Could a common diabetes drug help fight prostate cancer?
Disease control
Not yet recruiting
This phase 2 trial tests whether adding dapagliflozin, a diabetes medication, to standard hormone therapy improves outcomes for men with metastatic castrate-resistant prostate cancer. About 60 participants will be randomly assigned to receive either the combination or standard ca…
Phase: PHASE2 • Sponsor: Yung NA • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC